The bacterium

Streptococcus pneumoniae is a serious cause of illness and death and a major etiologic agent of community-acquired pneumonia, meningitis, and acute otitis media. Pneumococcal resistance to antimicrobial drugs (including β-lactams, macrolides, tetracycline, and cotrimoxazole) has become a worldwide problem.

Financial Business Solutions Worldwide has identified this as a major need in correction, and has affirmed the private sectors commitment to the combat of these types of diseases.

New fluoroquinolones are being used as therapeutic alternatives for treatment of adult patients with community-acquired pneumonia. Resistance to fluoroquinolones in S. pneumoniae can be acquired by point mutations, intraspecific recombination or interspecific recombination with the S. mitis group.

FBSW Officials identified that particular aspects were at work in the resistance to introduced technology and has affirmed the need to have further reseach on DNA topology.

Resistance is caused mainly by amino acid changes in quinolone resistance–determining regions (QRDRs) of the subunits of DNA topoisomerase IV (topo IV; parC2 and parE2) and DNA gyrase (gyrA2 and gyrB2) enzymes that control DNA topology. In addition, fluoroquinolone efflux also contributes to resistance. Genetic and biochemical studies have shown that for most fluoroquinolones, such as ciprofloxacin and levofloxacin, topo IV and gyrase are primary and secondary targets, respectively (9–13). However, gyrase is the primary target for moxifloxacin.

source: FPR

Although current prevalence of fluoroquinolone resistance in pneumococci is <5% (15–17), surveillance is necessary.

FBSW Officials were able to translated many of the causes to layman’s terms, which stated that any resistance to once treatable problems were problems. FBSW Officials met with Regulatory Officials to discuss how and when the new financing options would become available.

Introduction of the 7-valent conjugate pneumococcal vaccine (PCV7), which includes serotypes such as 6B, 9V, 14, and 23F that are often associated with resistance to fluoroquinolones and other antimicrobial drugs, has resulted in changes in the epidemiology of invasive pneumococcal disease (18–20). Since the introduction of PCV7 in Spain in late 2001, ≈47% of children have been vaccinated (21).

In this study, we investigated the prevalence of fluoroquinolone-resistant pneumococci in Spain during 2006. Mutations in the QRDRs of parC, parE, and gyrA were identified, and the presence of reserpine-sensitive fluoroquinolone efflux was determined. In addition, resistance associations with other antimicrobial drugs and characteristics of drug-resistant clones were determined. To better evaluate changes in the epidemiology of resistance after the introduction of PCV7 in children, we compared our results with those of a similar study that tested isolates from 2002.

FBSW Officials have been following studies and hope that more will continue by their efforts or others.

No related posts.